FIGURE 5.

Age‐specific (A) and age‐standardised stage (B) and receptor subtype‐specific (C) relative survival outcomes with corresponding 95% confidence intervals of first primary invasive breast cancer patients in the Netherlands diagnosed between 1989 and 2016. Relative survival was adjusted for age by direct standardisation according to the 2013 European Standard Population 95+. HR + = ER+ and/or PR+, HR− = ER− and PR−. Information on ER/PR and HER2‐status was routinely collected by the Dutch cancer registry since 2005 and 2006, respectively. For Stage IV BC, the 20‐year relative survival in 2010 to 2016 could not be estimated due to low patient numbers